title: Ipilimumab-induced hepatitis on 18F-FDG PET/CT in a patient with malignant melanoma.
abstract: A 78-year-old man with metastatic malignant melanoma underwent a restaging 18F-FDG PET/CT after initiation of ipilimumab therapy, a Food and Drug Administration-approved human monoclonal antibody targeting CTLA-4. PET/CT demonstrated intense FDG uptake fusing to poorly circumscribed hypodensities throughout the liver. Patient was experiencing high-grade fever, chills, and generalized fatigue at the time of imaging, as well as mildly elevated liver function tests. Patient was subsequently treated with corticosteroids for suspected ipilimumab-induced hepatitis, and the patient rapidly improved clinically. Follow-up PET/CT 2 months later revealed complete resolution of abnormal FDG uptake in the liver, confirming the diagnosis of ipilimumab-induced hepatitis.
authors.affiliation: From the *Division of Nuclear Medicine, Department of Radiology, and †Division of Oncology, Department of Medicine, New York University, New York, NY.
authors.forename: Roy A
authors.initials: RA
authors.lastname: Raad
authors.forename: Anna
authors.initials: A
authors.lastname: Pavlick
authors.forename: Rajni
authors.initials: R
authors.lastname: Kannan
authors.forename: Kent P
authors.initials: KP
authors.lastname: Friedman
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D019788:Fluorodeoxyglucose F18; D006505:Hepatitis / Q000000981:diagnostic imaging* / Q000209:etiology; D006801:Humans; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging* / Q000188:drug therapy; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
chemical_list: D000911:Antibodies, Monoclonal; D000074324:Ipilimumab; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18